Connect with us

Entrepreneur

“We are terrified to say the word ‘vagina'”- the founder educating the world on reproductive health

After years of being ignored and dismissed, Golnoush Golshirazi was diagnosed with endometriosis

Published

on

Dr Golnoush Golshirazi, co-founder and CEO of ScreenMe

Vaginal health is an essential part of a woman’s overall health. Yet, misconceptions surrounding this topic often lead individuals to feel dirty or ashamed when experiencing problems.

The lack of research into vaginal health and women’s health more generally seems only to perpetuate these misunderstandings, leaving women suffering in silence.

Dr Golnoush Golshirazi knows this too well. After years of being ignored and dismissed by healthcare professionals, she was diagnosed with endometriosis.

Wanting to make a change, the now researcher and women’s health advocate built her own business and launched ScreenMe, a platform that screens for every bacteria present in the vaginal microbiome and helps women better understand their reproductive health. She sat down with us to share her story.

Hi Golnoush, could you tell us a bit more about your background?

My background is molecular biology, with a PhD in genetics.

What inspired you to create ScreenMe?

My own personal health journey was what really ignited my passion to help others in the health space. It took thousands of pounds and many years until I got my endometriosis diagnosis. I felt constantly dismissed, ignored by professionals and unable to perform at my very best.

I always remember getting my period during one of my final exams for my university degree. I literally couldn’t move from my bed, and after ringing up, the invigilators were able to bring me my exam paper at least – however, the fact that I had to sit an exam when all I could think about was the huge pain I was experiencing (and be supposed to feel ‘grateful’ for this), is something that I will always remember.

After receiving my endometriosis diagnosis, I took a look back at this long and painful journey and vowed that I wanted to work to make sure this changed for others.

I saw that I could really use my own knowledge and expertise to advance healthcare responses and assist in creating solutions that genuinely worked for people. It wasn’t just this, but the wish to create a space where people felt heard and had access to the science that can really change their life – as this was something I struggled to find and wish I had looking back.

How would you describe ScreenMe in a few words?

Wow, that is a hard one. In just a few words I would say: answers and solutions, with care. This is because ScreenMe brings cutting-edge science to those who need it, but also pairs such with professional guidance, education and genuine support, to create solutions that work for you as an individual.

What makes ScreenMe different?

ScreenMe’s main difference I would say comes from making cutting-edge science accessible to the general public and bringing together the scientific, medical and holistic field for support.

As a team of scientists, medical professionals and holistic practitioners, and experts within the women’s health space we have decades of experience between us. This allows us to separate fact from fiction and really give advice and solutions that work for our community.

In a world which is moving towards a preventative and holistic care model – our team is so passionate about this and works towards such every day. Our team is also why we focus on education and awareness. We are aware from our own experiences that so many people know so little about intimate health and its long-term implications for fertility, infection, and disease – so it is our team who have focused our strategy on first educating society on the topic.

Then people can make informed, evidenced decisions as to what care, testing or support they need (if at all). We are passionate about not trying to push the ‘hard-sell’ on our product, but empower people with the agency to make the decisions that are right for them.

In terms of technicalities. ScreenMe is the only UK-based company that provides NGS-based screening of vaginal and seminal samples for bacteria and yeast allowing identification of all species present at very high accuracy.

Do you feel there is a lack of awareness around the importance of the vaginal microbiome and vaginal health in general?

As a society we are terrified to even say the word ‘vagina’, let alone open up discussions around this or provide adequate education. Most people do not even know the difference between the vulva and the vagina; or do not know that there are actually seven holes in their intimate area (most think there are three!).

So many of the people with vaginas we see each day have no clue about the implications of the symptoms they have been experiencing, or even the basics on how to look after their intimate health. This lack of awareness also extends out into the medical community.

Vaginal ecosystem and the role of the vagina in the bigger picture of health is hardly spoken about at med school. So many concerns could be prevented or resolved if people only had access to the correct information and services – so this is honestly something that I could speak about all day.

Such a severe lack of education is why we include a free one-to-one consultation with a practitioner for each of our tests, so that results can be explained and solutions can be curated.

This is also why we have published our free online Vaginal Health Clinic on our site where we provide the latest information regarding the vaginal microbiome and how this relates to a whole host of concerns, including recurrent infection, miscarriage, IVF success, thrush, cancer risk and much more.

How do you think we could start educating people on these subjects?

For me, the two most important ways to do this is through schools and educating the healthcare system itself.

Firstly, regarding schools, it is simply not enough to learn about the reproductive organs and their very basic functions. We need to ensure that there is effective and detailed education for all genders on the many layers of health, which includes intimate health, the role of hormones, menstrual conditions and disorders, sexual health and wellbeing, menopause, fertility complications, and so much more.

Schools are such a brilliant access point to allow people to understand from an early age, how to look after themselves, how to protect their health, what symptoms to look for, and also how to interact and understand others who may be suffering from particular health concerns or conditions.

We also are really passionate about educating the healthcare community about this topic. You would be amazed at how little is often required to be learnt about intimate health and so we do a lot of work with practitioners to improve their knowledge on this topic – including webinars and broadcasts.

Vaginal health often comes with a lot of stigma. How did you find establishing your business in this sector?

We actually started focusing on women’s health care in general and it was only through listening to our community that we realised what a huge gap there was in understanding, testing, services and support for intimate health. So, while there have been barriers in this pivot, we ultimately have had a core community who are so appreciative of the work we do for them and want to hear more about vaginal health.

I think reading the many positive reviews that state how we have changed people’s lives, really keeps us motivated. However, having a business in this sector has been difficult when approaching investors.

Intimate health is not always something that people are comfortable speaking about, so it is sometimes difficult to present appropriate data on such, or have productive conversations. Yet this is something we are striving to change every day!

What obstacles have you encountered on this journey?

I guess the main obstacle I have faced is actually being a woman. We hear all the time how gender disparities reveal themselves in the workplace and in society as a whole – but I guess you never really realise the extent of this until you experience them first-hand yourself.

Particularly when looking for investment, it is difficult to always communicate some of the many struggles that women face daily, and present them as a consumer market – despite women making the majority of household health-related spending decisions!

I have even been in a room myself with an investor and my co-founder (who is a man), and the investor asked me for a tea and assumed that I was the assistant. It was only when we started the meeting and my co-founder asked me to answer the first question, that the investor realised the mistake he had made. Of course, instances like this do serve well to light a fire in my belly, but it is unrealistic to say that they aren’t sometimes difficult to navigate.

Where are you with ScreenMe now?

We are currently really focusing on our expansion of intimate health services. This has a multi-pronged approach including: providing top-quality thought leadership, providing our services globally and expanding the network with whom we work with.

Each month we are receiving more attention and onboarding more partners, practitioners, clinics and customers. We want to expand out outreach and awareness, so that intimate health is something everyone understands and makes a part of their routine check-ups. As we build momentum, we are so excited to see this future starting to take shape in front of us, even if there is still a way to go yet.

We have also recently launched our semen microbiome testing service. This is so we can help everyone with their intimate health. The semen microbiome is also really important for a range of similar reasons, including fertility, IVF success, infection risk, and risk of disease.

Further, in the case of heterosexual partners, this allows us to treat couples as a pair and prevent reinfections – as there is no use for only one person to do all of the work to optimise intimate health, when their sexual partner is doing nothing!

What are you looking to achieve with ScreenMe?

We want to achieve a world in which intimate and reproductive health is a key feature of education and research and people are able to get the testing, support and services required to improve such. It is crazy to me that we are still using swab culture methods to investigate intimate health, when this was a method devised over 100 years ago.

NGS is an available technology which provides much greater accuracy and is able to screen 100 per cent of the bacteria present, rather than a selected panel of pre-selected bacteria as used in swab culture or PCR methods.

ScreenMe works to make this technology available to everyone, so that they can understand the full context of their microbiome, rather than just get a few pieces of the puzzle. So, really what we are working towards is empowering everyone with their intimate health and at the same time seriously powering up research which is crucial for better intimate and reproductive health.

Where do you see the company in the future?

I see ScreenMe as the go-to platform for people globally when it comes to their intimate and reproductive health. I see a trustworthy, science-based place where men and women find answers, solutions, support and education with all of this leading to lower risk of non-communicable diseases across society.

I have big ambitions, so I don’t just want to see ScreenMe changing and growing in the future, but I want to see the whole of intimate health as we know it changing due to ScreenMe’s work!

Dr Golnoush Golshirazi is the co-founder and CEO of ScreenMe. She is a Cambridge graduate, scientist and entrepreneur who advocates for women’s equality within the healthcare system. 

Entrepreneur

Kate Ryder headlines Women’s Health Week USA 2026 as full agenda goes live

Published

on

Women’s Health Week USA 2026 has unveiled its first populated agenda, anchored by an opening keynote from Kate Ryder, Founder and CEO of Maven Clinic, and featuring a cross-sector lineup shaping the next phase of scale in women’s health.

You can view the full agenda here.

Taking place May 13–14, 2026, at the New York Academy of Medicine, Women’s Health Week USA brings together the full women’s health ecosystem to focus on one central question: what does it take to move women’s health from innovation to institutional scale?

Kate Ryder will open Day 1 with a keynote drawing on her experience building Maven Clinic into the world’s largest virtual clinic for women’s and family health.

Under her leadership, Maven has partnered with employers and health plans to deliver care across fertility, maternity, postpartum, paediatrics, and menopause at scale.

Her perspective sets the tone for a program centered on commercialisation, partnership, and sustainable growth.

Beyond the opening keynote, the newly released agenda reflects the sector’s growing maturity.

Across two days, the program features 70+ speakers, with representation from leading organizations including the FDA, Planned Parenthood, CVS Health Ventures, Samsung Next, NIH, WHO, and Maven Clinic.

Sessions span investment and deal flow, clinical innovation, regulation, data and technology, and market expansion, alongside dedicated pitch sessions and curated 1:1 matchmaking designed to turn insight into action.

The agenda has been built to facilitate meaningful connections across the ecosystem, with partnerships positioned as the primary driver of scale.

As women’s health continues to attract institutional capital and global attention, Women’s Health Week USA 2026 offers a clear snapshot of where the market is heading, and who is shaping it.

The full agenda is now live, with additional speakers and partners to be announced in the coming months.

View the full programme here.

Continue Reading

Entrepreneur

Merck partners on intravaginal drug delivery device

Published

on

Calla Lily Clinical Care has partnered with Merck to support the intravaginal drug delivery platform Callavid in an effort to improve how vaginal medicines are given.

The collaboration will continue development of Callavid, described as a leak-resistant device that addresses challenges with self-administered vaginal therapies.

Callavid uses a small, tampon-shaped device with an integrated absorbent liner. It is inserted, remains in place during drug absorption, then is removed.

The platform is intended for use with medicines in fertility treatment, oncology and hormone therapy. Administration via the vaginal route can prompt patient anxiety about positioning, dosing accuracy and leakage.

The partnership is the first industry collaboration for the Callavid technology, which was developed by Calla Lily Clinical Care.

Thang Vo-Ta, co-founder and chief executive of Calla Lily Clinical Care, said: “This collaboration with Merck marks an important milestone in the development of Callavid, our novel vaginal drug delivery platform.

“Merck’s scientific heritage and forward-looking approach to innovation make them an ideal partner as we work to address long-standing unmet needs in women’s health.

“By improving how vaginal therapeutics are delivered and experienced, Callavid has the potential to enhance both patient outcomes and quality of life.

“We see this collaboration as a meaningful step towards translating our technology into real-world clinical and patient impact.”

Calla Lily Clinical Care is seeking to develop what it describes as the world’s first drug-device combination product to prevent threatened miscarriage and for IVF luteal phase support, the phase after ovulation when the body produces progesterone to support early pregnancy.

The device is also being developed to deliver therapeutics for oncology, menopause, infectious diseases and live biotherapeutics to reduce repeated antibiotic use.

Dr Lara Zibners, co-founder and chairman of Calla Lily Clinical Care, said: “Our initial engagement with Merck through the Merck Innovation Challenge in October 2024 was an important moment of alignment around the need for more patient-centric innovation in women’s health.

“As both a clinician and a patient, I have seen how profoundly drug delivery can shape treatment experience.

“This collaboration builds on that early dialogue and reflects a shared interest in rigorously exploring new approaches that may improve how therapies are delivered and experienced by patients.”

Continue Reading

Entrepreneur

US startup builds wearable hormone tracker

Published

on

Stanford graduates’ startup Clair is building a wearable hormone tracker for women, offering continuous, non-invasive monitoring.

The company, Clair, founded by Jenny Duan and Abhinav Agarwal, aims to build what its founders describe as a research-led, privacy-focused tool to help women see how hormone levels affect daily life.

Duan and Agarwal met in spring 2025 and began working on Clair shortly after. Over the past six months, they have been developing the technology and refining the company’s mission.

The device is designed to address gaps in women’s healthcare. Women remain underrepresented in medical research and clinical trials, leading to limited data and slower progress in understanding women’s health conditions.

According to Clair advisor and Stanford Medicine professor Brindha Bavan, hormone tracking in reproductive healthcare “improves our understanding of the function of and communication between the brain’s pituitary gland and ovaries or testes.

The pituitary gland is a small organ at the base of the brain that produces hormones regulating many bodily functions. The ovaries and testes are the primary reproductive organs that also produce sex hormones.

Hormonal health affects not only fertility and reproduction but also mental health, metabolism, energy levels and overall wellbeing.

Bavan said hormone tracking can “provide insight into menstrual cycle patterns and can aid with both diagnosing and assessing treatment for [various] conditions.”

“[Clair enables] patients [to] gain insight into their personal hormone fluctuations over different time periods,” Bavan said, “and share this information at healthcare visits to better understand and correlate any medical issues they are facing and avoid repeat blood draws.”

The device, which resembles a bracelet worn on the wrist, will connect to a mobile app, allowing all data processing to occur directly on the user’s phone rather than in external data centres.

“The device connects with an app so all of the processing happens on the app itself, not in a data centre like other devices. This is especially important given the current political climate around data privacy,” Agarwal said.

Clair also plans to pursue FDA approval and position itself as a medically credible device rather than solely a lifestyle product. The company is planning to launch a clinical trial at Stanford Medicine this spring.

Duan’s interest in women’s health and technology began as a Stanford undergraduate. At TreeHacks in 2024, she built apps focused on endometriosis, a condition where tissue similar to the lining of the womb grows outside of it.

She said a course on Philanthropy for Sustainable Development was particularly influential. “It was this class that sparked my interest in building a solution in [the women’s healthcare] space,” Duan said.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.